Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.
Cardiovascular disease (CVD) is the number one cause of death wordwide1. The cause of CVD is atherosclerosis. Cardiovascular risk does not correlate with clinical symptoms until considerable atherosclerotic disease progression. Consequently, early accurate CVD risk assessment is part of an established clinical strategy of primary prevention. A number of guidelines have been established for the prevention, diagnosis, evaluation and management of CVD. The goal being the reduction of cardiac events such as acute heart attack (myocardial infarction, MI) and stroke. CVD risk assessment is therefore a key aspect of clinical care for all individuals between the age of 40-79.
Clinical CV risk factors include hypertension, diabetes mellitus, chronic kidney disease, obesity, cigarette smoking and family history. The most important biomarkers for CV risk determination are lipids including total cholesterol, triglycerides, LDL and HDL cholesterol. Early epidemiological studies associated both total cholesterol and LDL cholesterol to CV risk. Current studies have shown that there is discordance in quite a number of individuals based on the standard lipid profile. Thus, the determination of lipoprotein particle (LDL-P) numbers offers a more accurate risk assessment especially in those individuals with other comorbid conditions. A simple determination of total cholesterol with its subgroups HDL and LDL is thus no longer sufficient. As a consequence it is recommended to consult further parameters providing data beyond the conventional lipid panel.
1. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. [Accessed September 12, 2012]; Natl Vital Stat Rep. 2011 59:1–126. www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf. [PubMed]
2. Sachdeva, A., et al., Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J, 2009. 157(1): 111-117 e2.
Numares offers an on-site technology for the assessment of cardiovascular risk, i.e. an in-depth lipoprotein analysis.
Beyond the standard lipid panel, the AXINON® System provides a more detailed and standardized analysis of the lipoprotein subclasses, via Magnetic Group Signaling (MGS®) technology.
Numares AXINON® lipoFIT® system* measures concentration, size and distribution of lipoprotein particles (which carry cholesterol) and determines the respective quantity of the key compounds triglycerides, cholesterol and phospholipids.
More information on the AXINON® System:
The AXINON® System enables comprehensive lipoprotein analysis and is suited for solid high-throughput operation with minimal hands-on time.
The combination of MGS® and the AXINON® System allows for spectral analysis with highly-reproducible results. The system is easy to use requiring minimal operator interaction. The system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
Numares licenses AXINON® Software, Magnetic Group Signaling (MGS®) technology and research methods/applications underlying our diagnostic products* to customers of the healthcare industry. For an individual licensing agreement, please get in contact with us.
To date, more than 2 million tests have been performed worldwide using Numares’ technology.
Address: 500 Chipeta Way, Salt Lake City, Utah 84108
Phone: (800) 522-2787
Boston Heart Diagnostics
Address: 175 Crossing Boulevard, Suite 500, Framingham, MA 01702
Phone: (877) 425-1252
Mayo Clinic Laboratories
Address: 3050 Superior Drive NW, Rochester, MN 55901
Phone: (800)-533-1710 / (507)-266-5700
MVZ Labor Ravensburg GbR (formerly Labor Dr. Gärtner)
Address: Elisabethenstr. 11, 88212 Ravensburg, Germany
Open: 8.00 am - 5.00 pm CET
Phone: +49 731 850705-40
MVZ Humangenetik Ulm GbR
Address: Karlstraße 31, 89073 Ulm, Germany
Open: 8.00 am - 5.00 pm
Phone: +49 731 850705-40